Welcome to the Microbiome Drug Database

Welcome to the Microbiome Drug Database: A live online tool, updated on a regular basis, that depicts the current microbiome pharma landscape. It is the most comprehensive global database of microbiome biotechs developing pharmaceuticals, consisting of over 310 companies and 1,350+ active research programsSee the full definitions and inclusion criteria of the analysis here.

Who should subscribe to Microbiome Drug Database:

Contract Development and Manufacturing Organisations

Contract Research Organisations

Sequencing Companies

Pharma and Venture Capital

Microbiome Biotechs

Why Subscribe?

Business Development

Identify potential biotech parnters by matching relevant research programs to your expertise. By keeping an eye on the development stages, you can make contact at the right time through our LinkedIn integration tool or company e-mail.

Strategic Decision Making

Keep an up-to-date view on the microbiome drug landscape to help with IP decisions, benchmarking, current analytics to approach investors as well as identify potential collaborations and partnerships.


Keep an up-to-date view on the microbiome pharmaceutical landscape, scout new investments, technologies and strategic partnerships as well as identify niches and trends. Gain access to our bi-annual market reports.

Competitive Analysis

See which and how many drugs are being developed for the specific indications, the stage of their development and modality.

Take a look inside...

BGAsset 2

Company subscriptions to the Microbiome Drug Database cost €4950 annually. Subscriptions are not automatically renewed and include up to 5x passes per organisation.